I'm looking for

SGO/ACCC Joint Education Collaborative: Optimizing Outcomes in Ovarian Cancer Using Personalized Medicine

 

Executive summary

The Society of Gynecologic Oncology (SGO) and the Association of Community Cancer Centers (ACCC) have been awarded a joint independent medical education grant from AstraZeneca and Merck. Together, SGO and ACCC will offer four accredited webinars (live and enduring) and up to six additional non-accredited media presentations (podcasts, clinical reviews) on the topic of delivering personalized medicine in a community setting. The webinar/virtual media programs are expected to launch in June 2021 and offered on a monthly rotation over the course of the year.

LATEST CONTENT –

“Ovarian Cancer Genetic Labs Physician/Patient Postcard”

Every patient with ovarian cancer should be offered testing aimed at informing targeted therapeutic decisions. This quick-reference, non-exhaustive guide provides a snapshot of germline and somatic testing options available for patients with ovarian cancer. Physicians and patients alike are encouraged to reference this PDF to printable postcard for more information about various labs, counseling options, and insurance information.

 

“Real-World Palliative Care in GYN Oncology: WHO (can do it), WHAT (is it), WHEN (to start), WHERE (can we do this) and WHY (is it so important)”

A round table discussion with a range of experts from academic centers to small community practice present examples of integrating palliative care in a variety of practice settings.

Moderator: Melissa Hardesty, MD, Alaska Women’s Cancer Care,

Speakers: Linda Smith, MD, Alaska Women’s Cancer Care, Kate Lally, MD FAAHPM, Dana Farber Cancer Institute, Carolyn Lefkowits, MD, MPH, UC Health Cancer Care, Lori Spoozak, MD, MHS, FACOG, FACS, University of Kansas, and Michael Pearl, MD, FACOG, FACS, FAAHPM, Stony Brook University Hospital.

 

“Conversations in The Clinic: Patient Perspectives on Genetic Testing” Podcast

Listeners will learn about the importance of genetic testing for ovarian cancer from a genetic counselor and a physician, and most importantly, from a patient.

Moderator: Ashley Stuckey, MD

Speakers Todd Tillmanns, MD, FACOG, West Cancer Center, and Leigha Senter-Jamieson, MS, LGC, Ohio State College of Medicine

 

Perfecting Placement of PARPS: Preventing Progression of Ovarian Cancer Webinar

In the fast-paced world of PARP inhibitor approvals in both the setting of maintenance and therapy in ovarian cancer, this panel of experts will assist practitioners to understand how to order germline and somatic testing for BRCA and HRD mutations. Speakers will discuss sequencing of PARP inhibitors as well as mitigating side effects. Additionally, they will discuss future directions for the use of PARP inhibitors as well as briefly discuss resistance to PARP inhibitors.

Moderator: John Farley, MD, COL, FACOG, FACS, Dignity Health – Cancer Institute, St. Joseph’s Hospital and Medical Center

Speakers: Premal Thaker, MD, MS, Washington University in St. Louis Siteman Cancer Center, Mary (“Maggie”) Mullen, MD, Washington University in St. Louis School of Medicine, and Todd Tillmanns, MD, FACOG, West Cancer Center

Coming Soon

 

Steering committee –

  • William Burke, MD, Stony Brook University Cancer Center
  • Melissa Hardesty, MD, MPH, Alaska Women’s Cancer Care
  • Premal Thaker, MD, MS, Washington University in St. Louis, Siteman Cancer Center
  • Ashley Stuckey, MD Brown University, Women and Infants Hospital
  • Todd Tillmanns, MD, FACOG, West Cancer Center
  • Jeff Lin, MD, City of Hope Medical Group
  • Roisin O’Cearbhaill, MD, Memorial Sloan Kettering Cancer Center
  • Charles Drescher, MD, Swedish Cancer Institute
  • John Farley, MD, COL, FACOG, FACS, Dignity Health Cancer Institute, St. Joseph’s Hospital and Medical Center
  • Leigha Senter-Jamieson, MS, LGC, The Ohio State University Wexner Medical Center

 

Target Audience

The target audience for this initiative includes medical oncologists, gynecologic oncologists, obstetrician-gynecologists, primary care physicians, advanced practice providers (nurse practitioners, physician assistants, oncology pharmacists), oncology nurses, pathologists, and other healthcare professionals (HCPs) involved in treating patients with ovarian cancer.

Learning Objectives

At the end of this educational initiative, participants should be able to:

  • Discuss the utility of novel biomarkers such as homologous repair deficiency (HRD) genomic instability for personalizing therapy in patients with ovarian cancer
  • Assess the clinical rationale for tumor and HRD genomic instability testing, including differentiation of germline/familial risk assessment versus tumor profiling in patients with ovarian cancer
  • Implement monitoring strategies and manage adverse events of emerging targeted therapies for patients with ovarian cancer
  • Explore strategies to improve patient engagement in shared decision-making regarding biomarker testing and personalized treatment in ovarian cancer along the continuum of care

Accreditations

The live/online webinars will each offer the following credits:

  • CME: 0.5 AMA PRA Category 1 Credit(s)™
  • ACPE credit: 0.5 contact hour
  • ANCC credit: 0.5 contact hour

Non-accredited educational materials: podcasts, case reviews, and other educational resources/tools

fellowship

Evaluation and Outcomes

The impact of participating in this initiative on clinical performance related to the optimal management of ovarian cancer will be assessed by comparing the response for pre-activity and post-activity tests (also designed by the Steering Committee). The outcomes analysis will assess the effectiveness of the programs in changing knowledge and competence, and intent to change behavior among learners in the following areas:

  • Learners will have a better understanding of utility of novel biomarkers such as homologous repair deficiency (HRD) genomic instability for personalizing therapy in patients with ovarian cancer
  • Learners will correctly assess the clinical rationale for tumor and HRD genomic instability testing, including differentiation of germline/familial risk assessment versus tumor profiling for therapeutic implications in ovarian cancer patients
  • Learners will be better prepared to monitor and manage adverse events for emerging targeted therapies for patients with and ovarian cancer
  • Learners will be more familiar with implementing strategies to improve engage patients in shared decision-making regarding biomarker testing and personalized treatment in ovarian cancer throughout the continuum of care starting at diagnosis
Advertisement

Join SGO Today

What you get out of membership changes your patient’s lives. What you give from your membership changes the world. Join your community today.

Become a Member

Educational materials that are part of accredited education (such as slides, abstracts, handouts, evaluation mechanisms, or disclosure information) must not contain any marketing produced by or for an ineligible company, including corporate or product logos, trade names, or product group messages. This activity has been supported by an independent medical education grant from AstraZeneca and Merck.